Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals develops and commercializes products for central nervous system, metabolic critical care, oncology, and more. Products include Ryanodex, Belrapzo, Bendeka, EP-4104, PEMFEXY, EA-114, and Vasopressin injection. The company has licensing agreements with Combioxin, SA, and AOP Orphan Pharmaceuticals GmbH. Eagle also collaborates with Tyme Technologies for the development of SM-88 to treat breast cancer and sarcomas.
Overview
Strengths
- With an appreciation Potential of 400.00%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (1.37) is lower than the sector mean (289.29).
- Price to book ratio (0.21) is lower than the sector mean (733.70).
- The company has low debt. Net Debt to EBITDA Ratio is 0.09 and it is lower than the sector mean.
- EV/EBITDA (0.72) is lower than the sector mean (51.86).
- EV/EBIT (0.85) is lower than the sector mean.
- Price to free cash flow (0.97) is lower than the sector mean.
- Strong EBITDA Margin of 24.48%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 1.1 |
| EV/EBITDA | 0.6 |
| Price/Free Cash Flow' | 0.7 |
| ROIC | 17.1% |
| Net Debt/EBITDA | 0.1 |